Меропенем (по материалам зарубежных публикаций)

В начало...

ЛИТЕРАТУРА

2. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: Fourth Information Supplement. NCCLS Document M100-S4 (ISBN 1-56238-172-5). Pennsylvania: NCCLS, 771 E. Lancaster Avenue, Villonova 1992.

3. Jones R.N., Aldridge K.E., Allen S.D. et al. Multicenter in vitro evalution of SM-7338, a new carbapenem. Antimicrob Agents Chemother 1989; 4: 33: 562-5.

4. Hoban D.J., Jones R.N., Yamane N. et al. In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated word-wide. Diagn Microbiol Infect Dis 1993; 11-12: 1: 299-305.

5. Schito G.C., Chezzi C., Ravizzola G. et al. In vitro activity of meropenem against clinical isolates in a multicentre study in Italy. J Antimicrob Chemother 1989; 9: 24: Suppl A: 57-72.

6. Sumita Y., Inoue M., Mitsuhashi S. In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338. Eur J Clin Microbiol 1989; 10: 8: 908-16.

7. Sarubbi F., Franzus B. Verghese A. Comparative activity of meropenem (SM-7338) against major respiratory pathogens and amikacin-resistant nosocomial isolates. Eur J Clin Microbiol Infect Dis 1992; 1: 11: 65-8.

8. Jones R.N., Barry A.L., Thornsberry C. In vitro studies of meropenem. J Antimicrob Chemother 1989; 9: 24: Suppl A: 9-29.

9. Wiedemann B., Zuhlsdorf M. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants. Ibid 197-205.

10. Fukasawa M., Sumita Y., Tada E. et al. In vitro antibacterial activity of meropenem (in Japanese). Chemotherapy (Tokyo) 1992; 4: 40: Supp; 1: 74-89.

11 . Edwards J.R., Turner P.J., Wannnop C. et al. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase. J Antimicrob Chemother 1989; 2: 33: 215-22.

12. Catchpole C.R., Wise R., Thornber D. In vitro activity of L-627, a new carbapenem. Antimicrob Agents Chemother 1992; 9: 36: 1928- 34.

13. Voutsinas D., Mavroudis T., Avlamis A. et al. In vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials. J Antimicrob Chemother 1989; 9: 24: Suppl A: 143-7.

14. Lewin C., Doherty C., Govan J. In vitro activities of meropenem. PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia. Antimicrob Agents Chemother 1993; 1: 37: 123-5.

15. Sader H.S., Jones R.N. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broadspectrum beta-lactam drugs. Eur J Clin Microbiol Infect Dis 1993; 5: 12: 384-91.

16. Neu H.C., Novelli A., Chin N.X. In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338. Antimicrob Agents Chemother 1989; 7: 33: 1009-18.

17. Yeo S.F., Livermore D.M. Comparative in vitro activity of biapenem and other carbapenems against Haemophilus influenzae isolates with known resistance mechanisms to ampicillin. J Antimicrob Chemother 1994; 4: 33: 861-5.

18. Jorgensen J.H., Maher L.A., Howell A.W. Activity of a new carbapenem antibiotic, meropenem, against Haemophilus influenzae strains with beta-lactamase and non-enzyme-mediated resistance to ampicillin. Antimicrob Agents Chemother 1991; 3: 35: 600-2.

19. Powell M., Seetulsingh P., Williams J.D. In vitro susceptibility of Haemophilus influenzae to meropenem compared with imipenem, five other beta-lactams, chloramphenicol and ciprofloxacin. J Antimicrob Chemother 1989; 9: 24: Suppl A: 175-81.

20. Bauernteind A., Jungwirth R., Schweighart S. In vitro activity of meropenem, imipenem, the penem HRE 664 and ceftazidime against clinical isolates from West Germany. Ibid 73-84.

21. Clarke A.M., Zemcov S.J. In vitro activity of meropenem against clinical isolates obtained in Canada. Ibid 47-55.

22. Jorgensen J.H., Maher L.A., Howell A.W. Activity of meropenem against antibiotic-resistant or infrequently encountered gram-negative bacilli. Antimicrob Agents Chemother 1991; 11: 35: 2410-4.

23. Harabe E., Kawai Y., Kanazawa K. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic. Drugs Exp Clin Res 1992; 18 (2): 37-46.

24. King A., Boothman C., Phillips I. Comparative in vitro activity of meropenem on clinical isolates from the United Kingdom. J Antimicrob Chemother 1989; 9: 24: Suppl A: 31-45.

25. Kayser F.H., Morenzoni G., Strassle A. et al. Activity of meropenem, against gram-positive bacteria. Ibid 101-12.

26. Visser M.R., Hoepelman I.M., Beumer H. et al. Comparative in vitro antivacterial activity of the new carbapenem meropenem (SM-7338). Eur J Clin Microbiol Infect Dis 1989; 12: 8: 1061-4.

27. Ravizzola G., Pinsi G., Gonzales R. et al. Antiacterial activity of the new carbapenem meropenem (SM-7338) against clinical isolates. Ibid 1053-61.

28. Linares J., Alonso T., Perez J.L. et al. Decreased susceptibility of penicillin-resistant pneumococci to twenty four beta-lactam antibiotics. J Antimicrob Chemother 1992; 9: 30: 279-88.

29. Sentochnik D.E., Eliopoulos G.M., Ferraro M.J. et al. Comparative in vitro activity of SM-7338, a new carbapenem antimicrobial agent. Antimicrob Agents Chemother 1989; 8: 33: 1232-6.

30. Nordmann P., Ronco E. In vitro antimicrobial susceptibility of Rhodococcus equi. J Antimicrob Chemother 1992; 4: 29: 383-93.

31. Yazawa K., Mikami Y., Ohashi S. et al. In vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L- 627 and imipenem against pathogenic Nocardia spp. Ibid 2: 29: 169- 72.

32. Aldridge K.E., Morice N., Schiro d.D. In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes. Antimicrob Agents Chemother 1994; 4: 38: 889-93.

33. Sheikh W., Pilkin D.H., Nadler H. Antibacterial activity of meropenem and selected comparative agents againts anaerobic bacteria at seven North American centers. Clin Infect Dis 1993; 6: 16: Suppl 4: 361-6.

34. Nord C.E., Lindmark A., Persson I. In vitro activity of L-627 against anaerobic bacteria. Eur J Clin Microbiol Infect Dis 1992; 8: 11: 757-60.

35. Goldstein E.J.C., Citron D.M., Cherubin C.E. et al. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole. J Antimicrob Chemother 1993; 3: 31: 363-72.

36. Appelbaum P.C., Spangler S.K., Jacobs M.R. Susceptibilities of 394 Bacteroides fragilis, non-B.fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents. Antimicrob Agents Chemother 1991; 6: 35: 1214-8.

37. Ferrara A., Grassi G., Grassi F.A. et al. Bactericidal activity of meropenem and interactions with other antibiotics. J Antimicrob Chemother 1989; 9: 24: Suppl A: 239-50.

38. Eng R.H., Padberg F.T., Smith S.M. et al. Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria. Antimicrob Agents Chemother 1991; 9: 35: 1824-8. 39. Wu P.J., Livermore D.M. Response of chemostat cultures of Pseudomonas aeruginosa to carbapenems and other beta-lactams. J Antimicrob Chemother 1990; 6: 25: 891-902.

40. Chen H.Y., Livermore D.M. Comparative in vitro activity of biapenem against enterobacteria with beta-lactamase-mediated antibiotic resistance. Ibid 1994; 3: 33: 453-64.

41. Kitzis M.D., Liassine N., Ferre B. et al. In vitro activities of 15 oral -lactams against Klebsiella pneumoniaeharboring new extended-spectrum -lactamases. Antimicrob Agents Chemother 1990; 34 (9):1783-6.

42. Labia R., Morand A., Tiwari K. et al. Interactions of meropenem with beta-lactamases, including enzymes with extended-spectrum activity against third-generation cephalosporins. J Antimicrob Chemother 1989; 9: 24: Suppl A: 219-23.

43. Livermore D.M., Yang Y. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms. Ibid 149-59.

44. Akova M., Bonfiglio G., Livermore D.M. Susceptibility to beta-lactam antibiotics of mutant strains of Xanthomonas maltophilia with high-and low-level constitutive expression of L1 and L2 beta-lactamases. J Med Microbiol 1991; 10: 35: 208-13.

45. Bonfiglio G., Livermore D.M. Effect of media composition on the susceptibility of Xanthomonas maltophilia to beta-lactam antibiotics. J Antimicrob Chemother 1991; 12: 28: 837-42.

46. Jones R.N., Gardiner R.V. Stability of SM-7338, a new carbapenem in mediums recommended for the susceptibility testing of anaerobic bacteria and gonococci. Diagn Microbiol Infect Dis 1989; 5-6: 12: 271-3.

47. Wise R., Ashby J.P., Andrews J.M. The antibacterial activity of meropenem in combination with gentamicin or vancomycin. J Antimicrob Chemother 1989; 9: 24: Suppl A: 233-8.

48. Ito A., Kaminaga T., Murano T. et al. In vitro studies of combinations of piperacillin and various antimicrobial agents on MRSA (in Japan). Chemotherapy (Tokyo) 1993; 11: 41: 1145-53.

49. MacKenzie F.M., Gould I.M., Chapman D.G. et al. Comparison of methodologies used in assessing the postantibiotic effect. J Antimicrob Chemother 1994; 8: 34: 223-30.

50. Garcia-Rodriguez J.A., Garcia S.J.E., Trujillano I. et al. Meropenem: in vitro activity and kinetics against organisms of the Bacteroides fragilis group. Ibid 1991; 5: 27: 599-606.

51. Odenholt-Tomqvist I. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem. Ibid 1993; 6: 31: 881-92.

52. Nadler H.L., Pitkin D.H., Sheikh W. The postantibiotic effect of meropenem and imipenem against selected bacteria. Ibid 1989; 9: 24: Suppl A: 225-31.

53. MacKenzie F.M., Gould I.M., Chapman D.G. et al. Postantibiotic effect of meropenem on members of the family Enterobacteriaceae determined by five methods. Antimicrob Agents Chemother 1994; 11: 38: 2583-9.

54. Livermore D.M. Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Ibid 1992; 9: 36: 2046-8.

55. Sanders C.C., Sanders W.E.Jr., Thomson K.S. et al. Meropenem: activity against resistant gram-negative bacteria and interactions with beta-lactamases. J Antimicrob Chemother 1989; 9: 24: Supp; A: 187-96.

56. Livermore D.M. Mechanisms of resistance to-lactam antibiotics. Scand J Infect Dis 1991; 78: Suppl: 7-16.

57. Cornaglia G., Guan L., Fontana R. et al. Diffusion of meropenem and imipenem through the outer membrane of Escherichia coli K-12 and correlation with their antibacterial activities. Antimicrob Agents Chemother 1992; 9: 36: 1902-8.

58. Raimondi A., Traverso A., Nikaido H. Imipenem- and meropenem-resistant mutants of Enterobacter cloacae and Proteus rettgeri lack porins. Ibid 1991; 6: 35: 1174-80.

59 . Satake S., Yoneyama H., Nakae T. Role of OmpD2 and chromosomal beta-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 1991; 8: 28: 199-207.

60. Cuffini A.M., Tullio V., Allocco A. et al. The entry of meropenem into human macrophages and its immunomodulating activity. Ibid 1993; 11: 32: 695-703.

61. Easmon C.S. Interaction of meropenem with humoral and phagocytic defences. Ibid 1989; 9: 24: Suppl A: 259-64.

62. Traub W.H., Leonhard B., Bauer D. Intracellular bactericidal activities of cefpirome and meropenem as compared with ciprofloxacin against Serratia marcescens. Med Microbiol Lett 1994; 6: 3: 173-80.

63. Fukasawa M., Sumita Y., Harabe E.T. et al. Stability of meropenem and effect of beta-methyl substitution on its stability in the presence of renal dehydropeptidase 1. Antimicrob Agents Chemother 1992; 7: 36: 1577-9.

64. Edwards J., Williams S., Nairn K. Therapeutic activity of meropenem in experimental infections. J Antimicrob Chemother 1989; 9: 24: Suppl A: 279-85.

65. Nilsson-Ehle I. Hutchison M., Haworth S.J. et al. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young healthy males. Eur J Clin Microbiol Infect Dis 1991; 2: 10: 85-8.

66. Bastain W., Bax R.P., Featherstone A. et al. The pharmacokinetics in volunteers of SM-7338 a new, broad spectrum, DPH-stable, carbapenem (abstract). In: 28th Interscience Conference on Antimicrobial Agents and Chemotherapy 1988; 215.

67. Bax R.P., Bastain W., Featherstone A. et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989; 9: 24: Suppl A: 311-20.

68. Burman L.A., Nilsson-Ehle I., Hutchison M. et al. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. Ibid 1991; 2: 27: 219-24.

69. Drusano G.L., Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis 1995; 96: Suppl: 11-6.

70. Fujii R., Yoshioka H., Fujita K. et al. Pharmacokinetic and clinical studies with meropenem in the pediatric field (in Japanese). Jpn J Antibiot 1992; 6: 45: 697-717.

71. Ljungberg B., Nilsson-Ehle I. Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men. Antimicrob Agents Chemother 1992; 7: 36: 1437-40.

72. Chimata M., Nagase M., Suzuki Y. et al. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Ibid 1993; 2: 37: 229-33.

73. Christensson B.A., Nilsson-Ehle I., Hutchison M. et al. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Ibid 1992; 7: 36: 1532-7.

74. Christensson B.A., Ljungberg B., Eriksson L. et al. Pharmacokinetics of meropenem in сystic fibrosis patients (abstract No. A73). Proceedings and Abstracts of the 34th Intersciense Conference on Antibacterial Agents and Chemotherapy. Orlando 1994.

75. Kanellakopoulou K., Giamarellou H., Papadothomakos P. et al. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 1993; 6: 12: 449-53.

76. Masaoka T., Sugryama H., Nagai K. et al. Therapeutic effects of meropenem against severe infections in petients with haematopoietic disorders (abstract). 8th Mediterranean Congress on Chemotherapy. 1992; May 24-29 1992.

77. Buckley M.M., Brogden R.N., Barradell L.B. et al. Imipenem/cilastatin: a reappraisal of its antibacterial activity, pharmacokinetics properties and therapeutic efficacy. Drugs 1992; 44 (3): 408-44.

78. Klugman K.P., Dagan R., Meningitis SG. Efficacy and safety of meropenem in the treatment of meningitis. Antimicrob Agents Chemother 1995; 39: 1140-6.

79. Pelser H.H., Meropenem SG. Meropenem or cephalosporins for bacterial meningitis (abstract). In: 8th International Congress of Chemotherapy 1993; 265.

80. Donnelly J.P., Horrevorts A.M., Sauerwein R.W. et al. High-dose meropenem in meningitis due to Pseudomonas aeruginosa. Lancet 1992; May 2: 339: 1117.

81. Chmelik V., Gutvirth J. Meropenem treatment of post-traumatic meningitis due to Pseudomonas aeruginosa. J Antimicrob Chemother 1993; 12: 32: 922-3.

82. Wiseman L.R., Wagstaff A.J., Brodgen R.N. et al. Drugs 1995; 50: 73-101.

83. Lami J.L., Wilson S.E., Hopkins J.A. Adjunctive antimicrobials in surgery of soft tissue infections: evalution of cephalosporins and carbapenems. Am Surg 1991; 12: 57: 769-74.

84. Nichols R.L., Smith K.W., Geckler R.W. et al. Meropenem versus imipenem/cilastatin in the treatment of hospitalised patients with skin and soft tissue infections. South Med J 1995; 88: 397-404.

85. Hemsell D., Martens M. A comparison of meropenem and clindamycin-gentamicin in the treatment of obstetric and gynaecologic infections (abstract). In: 9th Mediterranean Congress of Chemotherapy 1994; 100.

86. Winston D.J., Ho W.G., Bruckner D.A. et al. Beta-lactam antibiotic therapy in febrile granulocytopenic patients: a randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991; 115: 849-59.

87. Bergan T., Nord C.E., Thorsteinsson S.B. Effect of meropenem on the intestinal microflora. Eur J Clin Microbiol Infect Dis 1991; 6: 10: 524-7.

88. De Sarro A., Ammendola D., Zappala M. et al. Relationship between structure and convulsant properties of some -lactam antibiotics following intracerebroventricular microinjection in rats. Antimicrob Agents Chemother 1995; 39: 232-7.

Материал подготовлен С.М. Кузнецовой (Москва)